Clinical trial · Interventional
Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma
A Phase I, Multi-Center, Open-Label, Safety and Pharmacokinetic, Repeat-Dose Study of Oral Forodesine Hydrochloride in Patients With Refractory Cutaneous T-Cell Lymphoma
NCT00098332CI-TRIAL-00011292completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Forodesine (BCX-1777) may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory stage IIA, stage IIB, stage III, stage IVA, or stage IVB cutaneous T-cell lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| forodesine hydrochloride | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed cutaneous T-cell lymphoma * Refractory to prior treatment * Stage IIA, IIB, III, IVA, or IVB disease * Measurable disease PATIENT CHARACTERISTICS: Age * 18 and over Performance status * ECOG 0-2 Life expectancy * At least 3 months Hematopoietic * Not specified Hepatic * AST and/or ALT ≤ 3 times upper limit of normal * Hepatitis B and/or hepatitis C negative Renal * Creatinine clearance ≥ 40 mL/min Immunologic * Human T-cell lymphotrophic virus type I (HTLV-I) negative * HIV negative * No active serious infection not controlled by antibiotics Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No known impaired absorption of the gastrointestinal tract * No other illness that would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * More than 21 days since prior chemotherapy and recovered Endocrine therapy * Concurrent topical corticosteroids allowed provided patient remains on a stable dose Radiotherapy * No concurrent radiotherapy Surgery * Not specified Other * More than 30 days since prior investigational agents and recovered * No concurrent tanning bed use * No other concurrent therapy for cutaneous T-cell lymphoma
References
Publications (0)
Data not yet available
No reference posted for this study.